I am a molecular biologist with over 15 years of experience in academia and the pharmaceutical industry dedicated to the development of better diagnostics and treatments for human disease. At the National Institutes of Health (NIDCR), I designed and built immunoassays for a novel luminescent platform to quantitatively measure disease-specific serological markers in cancer and autoimmune disease. The platform, Luciferase Immunoprecipitation Systems (LIPS), has been used extensively by researchers across the NIH and by external partners. Over 60 peer-reviewed publications describe its use. At Crystal Bioscience, I contributed to the design, development and characterization of a humanized chicken for therapeutic antibody discovery. The OmniChicken™ and Crystal Bioscience, Inc. were acquired by Ligand Pharmaceuticals, Inc. in 2017. In 2021, I joined NextVivo, a seed-stage company founded by Stanford University professors Mark Davis and Calvin Kuo and backed by Khosla Ventures. As an Associate Director at NextVivo, I led a team of scientists using patient derived organoids to develop personalized cell therapies and antibody therapeutics.